Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.
- 1 March 1986
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 83 (6), 1911-1915
- https://doi.org/10.1073/pnas.83.6.1911
Abstract
Human T-lymphotropic virus type III (HTLV-III)/lymphadenopathy-associated virus (LAV) is a a newly discovered lymphotropic retrovirus that is cytopathic for helper/inducer T cells in vitro. This virus is the etiologic agent of the acquired immunodeficiency syndrome and related diseases. In the current study, we tested the capacity of purine and pyrimidine nucleoside derivatives to inhibit the infectivity and cytopathic effect of human T-lymphotropic virus type III in vitro. With the ribose moiety of the molecule in a 2',3'-dideoxy configuration, every purine (adenosine, guanosine, and inosine) and pyrimidine (cytidine and thymidine) nucleoside tested suppressed the virus, although the thymidine derivative seemed to have substantially less activity in our system than the others. In general, we observed essentially complete suppression of the virus at doses that were lower by a factor of 10 to 20 than those needed to inhibit the proliferation of the target T cells and the immune reactivity of normal T cells in vitro. An analysis of five adenosine congeners, which differed only in the sugar moiety, revealed that reduction (an absence of hydroxyl determinants) at both the 2' and 3' carbons of the ribose was necessary for an anti-viral effect, and an additional reduction at the 5' carbon nullified the anti-viral activity. These observations may be of value in developing a new class of experimental drugs for the therapy of human T-lymphotropic virus type III infections.This publication has 32 references indexed in Scilit:
- 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.Proceedings of the National Academy of Sciences of the United States of America, 1985
- Pharmacological inhibition of infectivity of HTLV-III in vitro.1985
- Monoclonal antibodies specific for p24, the major core protein of human T-cell leukemia virus type III.Proceedings of the National Academy of Sciences of the United States of America, 1985
- INHIBITION OF HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE III IN VITRO BY PHOSPHONOFORMATEThe Lancet, 1985
- Transfusion-Associated Acquired Immunodeficiency SyndromeThe New England Journal of Medicine, 1985
- RECOMBINANT HUMAN INTERFERON ALFA-A SUPPRESSES HTLV-III REPLICATION IN VITROThe Lancet, 1985
- Involvement of DNA polymerase alpha in simian virus 40 DNA replication.Online Journal of Public Health Informatics, 1978
- Effect of 2′, 3′-dideoxythymidine-5′-triphosphate on HeLa cell in vitro DNA synthesis: evidence that DNA polymerase α is the only polymerase required for cellular DNA replicationNucleic Acids Research, 1978
- RNA-directed DNA polymerase of Rous sarcoma virus: Initiation of synthesis with 70 S viral RNA as templateJournal of Molecular Biology, 1973
- Enzymic synthesis of deoxyribonucleic acid. XXXIV. Termination of chain growth by a 2',3'-dideoxyribonucleotideBiochemistry, 1969